| 1 |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
| 2 |
Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
|
| 3 |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
| 4 |
Obenauf AC, Zou Y, Ji AL, et al. Therapy-induced tumour secretomes promote resistance and tumour progression [J]. Nature, 2015, 520(7547): 368-372.
|
| 5 |
Nakahira K, Pabon Porras MA, Choi AM. Autophagy in Pulmonary Diseases[J]. Am J Respir Crit Care Med, 2016, 194 (10): 1196-1207.
|
| 6 |
Kenific CM, Debnath J. Cellular and metabolic functions for autophagy in cancer cells[J]. Trends Cell Biol, 2015, 25(1): 37- 45.
|
| 7 |
Liu H, He Z, Simon HU. Protective role of autophagy and autophagy-related protein 5 in early tumorigenesis[J]. J Mol Med (Berl), 2015, 93(2): 159-164.
|
| 8 |
Han W, Pan H, Chen Y, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells[J]. PLoS One, 2011, 6(6): e18691.
|
| 9 |
Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy[J]. Nat Cell Biol, 2010, 12(9): 814-822.
|
| 10 |
Hu YL, Jahangiri A, Delay M, et al. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy[J]. Cancer Res, 2012, 72(17): 4294-4299.
|
| 11 |
Klionsky DJ. Autophagy revisited: a conversation with Christian de Duve[J]. Autophagy, 2008, 4(6): 740-743.
|
| 12 |
Mehta P, Henault J, Kolbeck R, et al. Noncanonical autophagy: one small step for LC3, one giant leap for immunity[J]. Curr Opin Immunol 2014, 26: 69-75.
|
| 13 |
Sil P, Muse G, Martinez J. A ravenous defense: canonical and non-canonical autophagy in immunity[J]. Curr Opin Immunol, 2018, 50: 21-31.
|
| 14 |
Gao X, Zacharek A, Salkowski A, et al. Loss of heterozy-gosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer[J]. Cancer Res, 1995, 55 (5): 1002.
|
| 15 |
Mario G, Nisosantano M, Baehrecke EH, et al. Self-consumption: the interplay of autophagy and apoptosis[J]. Nat Rev Mol Cell Biol, 2014, 15(2): 81-94.
|
| 16 |
Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis[J]. Cancer Cell, 2006, 10(1): 51-64.
|
| 17 |
Hua L, Zhu G, Wei J. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy[J]. Cell Biol Int, 2018, 42(9): 1240-1249.
|
| 18 |
Yi QY, Bai ZS, Cai B, et al. HSV TK/GCV can induce cytotoxicity of retinoblastoma cells through autophagy inhibition by activating MAPK/ERK[J]. Oncol Rep, 2018, 40(2): 682-692.
|
| 19 |
Xu WX, Shi QQ, Qian XL, et al. Rab5a suppresses autophagy to promoto drug resistance in cancer cells[J]. AJ Translat Res, 2018, 10(4): 1229-1236.
|
| 20 |
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases [J]. Cell, 2010, 141(7): 1117-1134.
|
| 21 |
Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFRtargeting drugs[J]. Clin Cancer Res, 2006, 12(24): 7242-7251.
|
| 22 |
Hu X, Han B, Gu A, et al. A single-arm, multicenter, safety-monitoring, phase Ⅳ study of icotinib in treating advanced non-small cell lung cancer( NSCLC)[J]. Lung Cancer, 2014, 86(2): 207-212.
|
| 23 |
Park K, Tan EH, O′Byrne K, et al. Afatinib versus gefitinib as firstline treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial [J]. Lancet Oncology, 2016, 17(5): 577.
|
| 24 |
Arulananda S, Do H, Musafer A, et al. Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12 (11): 1728-1732.
|
| 25 |
Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer[J]. Nat Med, 2013, 19(11): 1389-1400.
|
| 26 |
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutationand resistance of non-small cell lung cancer to gefitinib[J]. N Engl J Med, 2005, 352(8): 786-792.
|
| 27 |
Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP[J]. Proc Natl Acad Sci U S A, 2008, 105(6): 2070-2075.
|
| 28 |
Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer[J]. Nat Med, 2012, 18(4): 521-528.
|
| 29 |
Yang JJ, Yao W, Qian GS, et al. Rab5-mediated VE-cadherin internalization regulates the barrier function of the lung microvascular endothelium[J]. Cell Mol Life Sci, 2015, 72(24): 4849-4866.
|
| 30 |
Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non small cell lung cancer harboring EGFR T790M[J]. Nat Med, 2015, 21(6): 560-562.
|
| 31 |
Henson E, Chen Y, Gibson S. EGFR family members′regulation of autophagy is at a crossroads of cell survival and death in cancer[J]. Cancers (Basel), 2017, 9: pii: E27.
|
| 32 |
Zhang ZL, Guo M, Zhao SF, et al. The update on transcriptional regulation of autophagy in normal and pathologic cells: A novel therapeutictarget[J]. Biomed Pharmacother, 2015, 74: 17-29.
|
| 33 |
Alexandrova AY, Kopnin PB, Vasiliev JM, et al. ROS up-regulation mediates Ras-induced changes of cell morphology and motility[J]. Exp Cell Res, 2006, 312: 2066-2073.
|
| 34 |
Zhou YY, Li Y, Jiang WQ, et al. MAPK/JNK signalling: A potential autophagy regulation pathway[J]. Biosci Rep, 2015, 35: pii: e00199.
|
| 35 |
Yip PY. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer[J]. Transl Lung Cancer Res, 2015, 4: 165-176.
|
| 36 |
Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1[J]. Nat Cell Biol, 2011, 13: 132-141.
|
| 37 |
Lachkar S, Senovilla L, Kepp O, et al. Direct interaction between STAT3 and EIF2AK2 controls fatty acid induced autophagy[J]. Autophagy, 2013, 9: 415-417.
|
| 38 |
Ernst M, Putoczki TL. Stat3: Linking inflammation to (gastrointestinal) tumourigenesis[J]. Clin Exp Pharmacol Physiol, 2012, 39: 711-718.
|
| 39 |
Demaria M, Camporeale A, Poli V. Stat3 and metabolism: How many ways to use a single molecule？[J]. Int JCancer, 2014, 135: 1997-2003.
|